Loading news article.

NewsGlobeNewswire

Clene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights

Nov 4, 2026, 08:30 ET · Published

Article summary

Clene Inc. (Nasdaq: CLNN), a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced its third quarter 2026 financial results and provided updates on its CNM-Au8 programs.

An excerpt from the original article.

Related companies

Clene Inc. Common StockCLNNView stock

Analyzed by WAPE AI.

Preparing English content…

Repost

Comments —

Loading comments…